NXTC - NextCure, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
48.76
+0.49 (+1.02%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close48.27
Open48.33
Bid0.00 x 1000
Ask0.00 x 800
Day's Range48.20 - 50.76
52 Week Range13.86 - 109.00
Volume139,830
Avg. Volume343,496
Market Cap1.338B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.03
Earnings DateNov 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est71.00
  • GlobeNewswire

    NextCure to Present at 9th Annual SVB Leerink Global Healthcare Conference

    NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the 9th Annual SVB Leerink Global Healthcare Conference in New York on February 25 at 9:00 am. A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.

  • Eli Lilly ends deal with NextCure worth up to $1.4B for the local biotech
    American City Business Journals

    Eli Lilly ends deal with NextCure worth up to $1.4B for the local biotech

    Under the deal, inked in November 2018, NextCure gave Eli Lilly access to its proprietary platform for research aimed at developing and commercializing new cancer therapies.

  • GlobeNewswire

    NextCure to Present at the 38th Annual J.P. Morgan Healthcare Conference

    BELTSVILLE, Md., Jan. 06, 2020 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.

  • 3 Healthcare Stocks With 100% Street Support
    TipRanks

    3 Healthcare Stocks With 100% Street Support

    Getting everyone on board isn’t always easy. Whether out at a restaurant ordering a shared platter with friends, or choosing a song from a playlist, it can be challenging to reach an agreement with those around you, and mostly impossible to please everyone at the same time.Of course, there are exceptions to the rule, and even the analysts on Wall Street all reach the same conclusion at times. Common disagreements on whether a stock is over-sold or over-bought, are periodically put aside as a consensus is reached about one’s potential.The odds are even harder to beat when considering the future potential of stocks from the same sector, so when everyone is singing from the same hymn sheet, it’s time to take notice.With this in mind, we used TipRanks’ Analysts' Top Stocks tool to home in on 3 stocks in the same sector (healthcare in our case) which have received nothing but bullish shout outs in the last three months, and which, additionally, all have a Strong Buy consensus rating. Let’s get the lowdown.NextCure Inc (NXTC)This biotech, which develops new cancer drugs, has been turning heads on the Street recently.As is common in the sector, NextCure’s share price skyrocketed at the start of November following the release of promising data from early clinical trial results for its cancer treatment, NC318, an antibody targeting Siglec-15 (an immuno-suppressive protein of the tumor micro-environment). The news caused the share price to soar almost 250% in a single day. Roughly a week later, the stock crashed by over 50% in a session, following updated data which wasn’t quite as promising.These shenanigans are common in the volatile world of biotechs, and not much is to be deduced from the wild price swings following such early results. As it happens, in this case, NextCure’s pedigree is very strong.The company’s founder is Dr. Lieping Chen, Professor of Immunobiology at Yale University, and discoverer of the PD-L1/PD1 pathway, which showed that blocking the interaction between PD-1 and PD-L1 by monoclonal antibodies had a positive effect on the immune system’s ability to eliminate tumors.NextCure has other cancer treatment medicines in the pipeline, and BTIG’s Robert Hazlett sets out the bullish case for the recently listed biotech.The 5-star analyst noted, “NC318 has material promise as it modifies the activity of S15, a potent immunosuppressive protein, in the tumor microenvironment (TME). Normally S15 is expressed at very low levels, but in the TME, it is materially overexpressed, creating the potential for a meaninful immuno-oncology target, as it is present in 15-25% in NSCLC, TNBC, ovarian and head & neck cancers, providing NC318 with multi-billion dollar potential. NextCure is also employing its FIND-IO discovery platform toward developing other IO therapies.”Therefore, Hazlett initiated coverage on NextCure with a Buy rating, and set a price target of $61. As share prices surged at the end of last week, the upside potential comes in at a modest 4%. (To watch Hazlett’s track record, click here)Three other analysts tracked over the last 3 months all rate NextCure as a Buy, which collectively adds up to a Strong Buy consensus rating. The fellow analysts are even more bullish than Hazlett, as the average price target of $68.75 implies potential upside of 17%. (See NextCure stock analysis on TipRanks) Axsome Therapeutics Inc (AXSM)On to the Street’s next promising healthcare choice, and we encounter a recurring theme. Axsome therapeutics is up by over 115% in the last week, following -you guessed it- positive trial data.The CNS (central nervous system) focused biotech, released results for its experimental anti-depression drug, AXS-05, showing the treatment met the primary endpoint in a Phase 3 clinical trial. Axsome plans to submit an application to the FDA for approval of the therapy in the second half of 2020.The positive results back up a previous phase 2 trial in which AXS-05 exhibited superior efficacy compared to Bupropion for both MDD (major depressive disorder) and smoking cessation.BTIG’s Robert Hazlett also covers Axsome and reminds investors of the company’s potential. “Taken together, these data show consistent, rapid, durable, and significant anti-depressant effects of AXS-05 and de-risk AXS-05 in MDD; with additional strong results, we also modestly reduce our discount for AXS-05 in treatment resistant depression (TRD) as well… Given AXS-05’s relatively clear path to approval, consistent efficacy profile, and oral delivery, we now formally include M&A exit optionality into our valuation… We believe there is evidence that AXS-05’s broad activity at multiple CNS receptors (NMDA, Sigma-1, others) has the potential to support its use in multiple large CNS indications with peak sales potential of several billion dollars,” he said.Therefore, Hazlett reiterated his Buy recommendation on Axsome, alongside a price target of $97.A full house of 9 Buys bestows on Axsome Strong Buy status. As the average price target stands at $123.50, there is further room for growth in the shape of 23%. (See Axsome stock analysis on TipRanks) iRhythm Technologies (IRTC)Digital healthcare company, iRhythm Technologies, has had a poor 2019, with its share price losing 12% year-to-date. Looking at the bigger picture, though, the cardiac device specialist still has a lot going for it.The company’s flagship product, Zio, is a wearable patch that detects cardiac symptoms and has gained quick adoption due to ease of use and accurate data readings.iRhythm’s marketing strategy of getting a foot in the door at doctors’ offices to set up new accounts, has seen use of the Zio XT patch in diagnostic situations rise from 10% of accounts at the end of 2016 to 70% by 2018’s close. A further addition of sales representatives indicates the company will see out 2019 with as many as 140 sales reps, compared to 110 at the end of 2018, and significantly more than 2017’s 86.RBC’s Brandon Henry is with the bulls on iRhythm. The 4-star analyst noted, “We believe IRTC’s core business will continue to perform well, led by new sales rep adds, increased sales rep productivity, the full commercial launch of Zio AT (which should drive additional XT sales), and continued penetration in large integrated hospitals.”To this end, Henry reiterated an Outperform rating on the medical instrument maker, alongside a price target of $109. Should the target be met, gains of almost 79% could be in line over the next 12 months. (To watch Henry’s track record, click here)Where does the Street stand on iRhythm? The Street agrees with Henry. The cardiac device developer has a Strong Buy consensus rating, based on 3 Buy recommendations. The average target price adds 50 cents to the RBC analyst’s target and comes in at $109.50, implying handsome upside potential of 80%. (See iRhythm's price targets and analyst ratings on TipRanks)

  • Is NextCure, Inc. (NXTC) A Good Stock To Buy ?
    Insider Monkey

    Is NextCure, Inc. (NXTC) A Good Stock To Buy ?

    We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]

  • GlobeNewswire

    NextCure to Present at Piper Jaffray 31st Annual Healthcare Conference

    NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that the company will present at the Piper Jaffray 31st Annual Healthcare Conference in New York on December 3, 2019 at 2:00 pm ET. A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.

  • GlobeNewswire

    NextCure Announces Closing of Public Offering

    BELTSVILLE, Md., Nov. 19, 2019 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.

  • Benzinga

    The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio ...

  • GlobeNewswire

    NextCure Announces Pricing of Public Offering of Common Stock

    BELTSVILLE, Md., Nov. 14, 2019 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.

  • GlobeNewswire

    NextCure Announces Proposed Public Offering of Common Stock

    NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced a proposed public offering of 3,200,000 shares of its common stock. In addition, NextCure intends to grant the underwriters a 30-day option to purchase up to an additional 480,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the common stock to be sold in the offering will be offered by NextCure.

  • Benzinga

    Analyst Trims NextCure Price Target Following SITC Presentation, Still Sees Big Upside

    NextCure Inc (NASDAQ: NXTC) shares are settling down after the volatile run in the past few sessions. Alec Stranahan reiterated an Overweight rating price on NextCure and reduced the price target from $92 to $89. With the large unmet need for new immunotherapy approaches for cancer, the unique mechanism of action of NextCure's NC318 and NC410 is attractive, Stranahan said in a note.

  • GlobeNewswire

    NextCure Reports Third Quarter 2019 Financial Results

    BELTSVILLE, Md., Nov. 12, 2019 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.

  • Benzinga

    These Are The Winners Of The Inaugural WeTrader Paper Trading Competition

    The WeTrader Paper Trading Competition , a 5-week paper trading contest hosted by the zero-commission trading platform Webull, has officially ended. Here’s a look at how the 83 contestants—the top 10 portfolios ...

  • GlobeNewswire

    NextCure Presents Updated Clinical Data from NC318 Phase 1/2 Clinical Trial at the 34th Annual Meeting of Society for Immunotherapy of Cancer (SITC) and Announces Initiation of Phase 2 Portion of the Trial

    NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that updated clinical results from the Phase 1 portion of its ongoing trial with NC318, a monoclonal antibody targeting Siglec-15 (S15), were presented at the SITC annual meeting. In addition, NextCure announced the initiation of the Phase 2 portion of its ongoing Phase 1/2 clinical trial of NC318. The most common tumor types enrolled included: non-small cell lung cancer (NSCLC) (13 patients), ovarian cancer (seven patients), melanoma (seven patients), breast cancer (four patients) and colorectal cancer (three patients).

  • GlobeNewswire

    NextCure to Host and Webcast Event at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing next-generation immunomedicines for cancer and other immune-related diseases, today announced that the company will host and webcast an event with its Chief Medical Officer at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on Saturday, November 9, 2019 at 6:30 p.m. Eastern Time at the Gaylord National Hotel & Convention Center in National Harbor, Maryland. At the event, NextCure will discuss updated clinical results from the Phase 1 portion of its ongoing trial with NC318 that are being presented earlier in the day at SITC. Institutional investors and analysts are requested to rsvp to Drew Phillips at drew.phillips@westwicke.com or by phone at 443-213-0497.

  • InvestorPlace

    WeWork IPO was a Failure – These 2 IPO Stocks are Surging

    I always keep tabs on IPO stocks, as I'm a big believer in investing early, but I'll be the first to tell you that it's not always easy.If you're looking for large, long-term gains - and who isn't? - investing early is necessary. One example you probably know is Facebook (NASDAQ:FB). If you'd invested five years ago, you'd be richer today than if you'd just invested this year.But on the road to greatness, Facebook hit its share of roadblocks. In fact, the stock went absolutely nowhere for over a year after its IPO in 2012.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe market is full of stories like that. And IPO stocks don't always go on to do great things. Some of the most anticipated IPOs fizzle out before they even begin, as we recently saw with the whole WeWork debacle. * 7 Stocks to Buy in November In the space of just one month, the coworking office space company filed for an IPO, saw potential creditors flee once they got a look at its financials, yanked the IPO entirely, and ultimately fired its scandalous CEO, Adam Neumann. WeWork was once privately valued at $47 billion, but now that seems to have gone up in smoke.One big problem here is that once WeWork got into the spotlight, the hype - and the valuation - got out of control. I've seen it many times before, but sooner or later, the honeymoon ends and reality sets in. Put These Two IPO Stocks On Your Watch ListRight now, the best-performing IPO stocks are also the least talked-about, which is pretty telling. A couple stand out to me right now. They might not have a cool enough story to get on TV, but you'll definitely want to put them on your watch list all the same.InMode (NASDAQ:INMD) is a medical device company based in Israel. Specifically, its products are used in minimally invasive surgical and aesthetic procedures in the fields of dermatology, cellulite removal, and gynecology. It's a $1 billion company by market cap, was founded in 2008, and has been profitable for years. Financial buzz puts the sector InMode is going after, medical aesthetics, at $22.2 billion in five years.INMD stock is up 133% since its IPO this August. Even better, its sales are on a steady climb, too - from $53 million in 2017 to $187 million projected for 2020. That would be 253% sales growth in just three yearsThe other promising, under-the-radar IPO is NextCure (NASDAQ:NXTC). It's a clinical stage biotech focused on cancer treatments. The company is pretty small at a market cap of less than $600 million, but it has a deal with drug giant Eli Lilly (NYSE:LLY) that could result in up to $1.4 billion in milestone payments. The stock is up 30% since its IPO this May. Given the lucrative deal with Big Pharma, I wouldn't be surprised to see much better gains down the road.If you've never heard of either of these IPO stocks before, I wouldn't be surprised. They've been neglected by the media "hype machine"… and that's promising. It tells me that there's still a lot of potential for future gains - gains that these companies can earn the old fashioned way: by selling more product and delivering shareholder value, year after year.I'll be keeping an eye out for that. You should, too.Matthew McCall left Wall Street to actually help investors -- by getting them into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), and +1,044% in Tesla (TSLA), just to name a few. Click here to see what Matt has up his sleeve now. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Buy-and-Hold Stocks to Play Investing's Biggest Trends * 7 Stocks to Buy in November * 5 Strong Buy Stocks Under $5 With Massive Upside Potential The post WeWork IPO was a Failure a€“ These 2 IPO Stocks are Surging appeared first on InvestorPlace.

  • GlobeNewswire

    NextCure Announces Promotion of Timothy Mayer, Ph.D., to Chief Operating Officer

    BELTSVILLE, Md., Oct. 02, 2019 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.

  • GlobeNewswire

    NextCure to Present Clinical Data from NC318 Phase 1/2 Clinical Trial at 34th Annual Meeting of SITC

    BELTSVILLE, Md., Oct. 01, 2019 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.

  • GlobeNewswire

    NextCure to Present at Morgan Stanley 17th Annual Global Healthcare Conference

    NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that the company will present at the Morgan Stanley 17th Annual Global Healthcare Conference in New York on September 10, 2019 at 10:00 am ET. A live audio webcast will be available through the Events and Presentations page of the Investors section of the company’s website at www.nextcure.com. NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.

  • GlobeNewswire

    NextCure Reports Second Quarter 2019 Financial Results

    BELTSVILLE, Md., Aug. 12, 2019 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.

  • What Kind Of Shareholder Owns Most NextCure, Inc. (NASDAQ:NXTC) Stock?
    Simply Wall St.

    What Kind Of Shareholder Owns Most NextCure, Inc. (NASDAQ:NXTC) Stock?

    The big shareholder groups in NextCure, Inc. (NASDAQ:NXTC) have power over the company. Large companies usually have...

  • 2 Small-Cap Biotech IPOs You Should Know About
    Motley Fool

    2 Small-Cap Biotech IPOs You Should Know About

    The public markets are awash in new biopharmaceutical companies, but these two appear to be overlooked.

  • GlobeNewswire

    NextCure Reports First Quarter 2019 Financial Results

    BELTSVILLE, Md., June 10, 2019 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.